Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $0.00 | $3.69M | $59.6M | $197M | $376M |
| Revenue growth | — | — | — | — | — | 1517.1% | 229.7% | 91.3% |
| Operating income | -$19.7M | -$43.1M | -$137M | -$207M | -$302M | -$241M | -$128M | -$12.2M |
| Operating margin | — | — | — | — | -8183.0% | -404.5% | -65.3% | -3.3% |
| Net income | -$19.3M | -$42.0M | -$136M | -$206M | -$311M | -$262M | -$140M | -$16.1M |
| Net margin | — | — | — | — | -8449.8% | -439.8% | -71.3% | -4.3% |
| EPS (diluted) | -$15.53 | -$22.78 | -$3.80 | -$4.18 | -$5.66 | -$3.78 | -$1.16 | -$0.13 |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$14.1M | -$42.8M | -$113M | -$175M | -$258M | -$247M | -$112M | -$5.63M |
| Capital expenditures | $0.00 | $295K | $321K | $995K | $333K | $428K | $143K | $686K |
| Free cash flow | -$14.1M | -$43.1M | -$113M | -$176M | -$258M | -$247M | -$112M | -$6.31M |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $39.4M | $63.3M | $65.1M | $96.4M | $53.6M | $88.4M | $71.3M | $42.9M |
| Total assets | — | $107M | $298M | $408M | $449M | $341M | $349M | $433M |
| Total liabilities | — | $5.55M | $27.6M | $110M | $240M | $253M | $191M | $243M |
| Long-term debt | — | — | $0.00 | $72.3M | $198M | $202M | $107M | $108M |
| Shareholders' equity | -$24.0M | -$65.0M | $271M | $298M | $210M | $88.7M | $158M | $189M |
| Retained earnings | — | -$66.3M | -$202M | -$408M | -$720M | -$982M | -$1.12B | -$1.14B |
| Shares (wtd avg diluted) | — | 1.84M | 35.7M | 49.4M | 55.0M | 69.3M | 121M | 127M |
Every figure is extracted from Arcutis Biotherapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.